Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission

Bone Marrow Transplantation

Volumn 22, Issue 1, 1998, Pages 13-19

  Jerjis, Sh ^a   Roovers, E ^a   Muus, P ^a   Schaap, N ^a   De Witte, T ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukemia; Autologous bone marrow transplantation; Conditioning regimens; First complete remission; Idarubicin

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TRANSFUSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE COUNT; FEMALE; HUMAN; HYPOPLASIA; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; RECURRENCE RISK; THROMBOCYTE COUNT; WHOLE BODY RADIATION;

EID: 0031822004     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701279     Document Type: Article

References (52)

1. Bishop JF. Etoposide in the treatment of leukemias. Semin Oncol 1992; 19: 33-38.
2. Ruutu T, Elonen E. Etoposide, 6-thioguanine and idarubicin, an oral combination regimen (ETI) for the induction treatment of acute leukemia. Hematol Oncol 1991; 9: 87-92.
3. Reiffers J, Huguet F, Stoppa AM et al. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia 1996; 10: 389-395.
4. Pignon B, Witz F, Desablens B et al. Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam Group. Br J Haematol 1996; 94: 333-341.
5. Curtis JE, Minden MD, Minkin S, McCulloch EA. Sensitivities of AML blast stem cells to idarubicin and daunorubicin: a comparison with normal hematopoietic progenitors. Leukemia 1995; 9: 396-404.
6. Champlin R, Gajewski J, Nimer S et al. Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment. J Clin Oncol 1990; 8: 1199-1206.
7. Stein AS. O'Donnell MR, Chai A et al. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission. J Clin Oncol 1996; 14: 2206-2216.
8. Bishop JF, Matthews JP. Young GA et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia (see comments). Blood 1996; 87: 1710-1717.
9. Cassileth PA, Lynch E, Hines JD et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992; 79: 1924-1930.
10. Schiller G, Gajewski J, Territo M et al. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 1992; 80: 2977-2982.
11. Reiffers J, Gaspard MH, Maraninchi D et al. Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: a prospective controlled trial. Br J Haematol 1989; 72: 57-63.
12. Zittoun RA, Mandelli F, Willemze R et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell-Adulto (GIMEMA) Leukemia Cooperative Groups (see comments). New Engl J Med 1995; 332: 217-223.
13. Cassileth PA, Andersen J, Lazarus HM et al. Autologous bone marrow transplant in acute myeloid leukemia in first remission. J clin Oncol 1993; 11: 314-319.
14. Lambertenghi Deliliers G, Annaloro C, Delia Volpe A et al. Single-institution results of autologous bone marrow transplantation in acute myeloid leukemia. Haematologica 1995; 80: 136-141.
15. Meloni G, Vignetti M, Andrizzi C et al. ABMT for children AML: Italian experience. GITMO-AIEOP Groups. Bone Marrow Transplant 1991; 3: 80-83.
16. Raemaekers J, De Witte T, Schattenberg A, Van der Lely N. Prevention of leukemic relapse after transplantation with lymphocyte depleted marrow by intensification of the conditioning regimen with a 6-day continuous infusion of anthracyclines. Bone Marrow Transplant 1989; 4: 167-171.
17. Schattenberg A, Mensink E, de Witte T. Intensification of the conditioning regimen by the addition of anthracyclines results in a higher incidence of sustained molecular remissions after allogeneic bone marrow transplantation for chronic myeloid leukaemia with marrow depleted of lymphocytes by counter-flow centrifugation. Cas Lek Cesk 1996; 135: 239-243.
18. Schaap N, Schattenberg A, Bar B et al. Outcome of transplantation for standard-risk leukaemia with grafts depleted of lymphocytes after conditioning with an intensified regimen. Br J Haematol 1997; 98: 750-759.
19. Muus P, De Witte T, Schattenberg A. Intensification of the conditioning regimen for allogeneic bone marrow transplantation in recipients of T-cell depleted graft by the addition of anthracyclines. Leuk Lymphoma 1992; 7: 1-6.
20. Muus P, Donnelly P, Schattenberg A et al. Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent. Semin Oncol 1993; 20: 47-52.
21. Van de Ouweland F, De Witte T, Geerdink P, Haanen C. Enrichment and cryopreservation of bone marrow progenitor cells for autologous reinfusion. Cryobiology 1982; 19: 292-298.
22. Zittoun R, Jehn U, Fiere D et al Alternating v repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group. Blood 1989; 73: 896-906.
23. Zittoun R, Mandelli F, De Witte T et al. Relative value of allogeneic BMT, autologous BMT and intensive chemotherapy during the first complete remission (CR) of acute myelogenous leukemia (AML). An interim analysis of the AML8 EORTC-GIMEMA protocol. Bone Marrow Transplant 1990; 1: 56-58.
24. Carella AM, Carlier P, Pungolino E et al. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group. Leukemia 1993; 7: 196-199.
25. Buchner T, Urbanitz D, Emmerich B et al. Mutlicentre study on intensified remission induction therapy for acute myeloid leukemia. Leukemia Res 1982; 6: 827-831.
26. Simonsson B, Nilsson B, Hokland P. Roquinimex (Linomide) versus placebo in patients with AML after ABMT. Bone Marrow Transplant 1997; 19: (Suppl. 2): S139 (p 555).
27. Keating MJ, Smith TL, Kantarjian H et al. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 1988; 2: 403-412.
28. Berman E, Heller G, Santorsa J et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77: 1666-1674.
29. Lambertenghi Deliliers G, Annaloro C, Oriani A et al. Idarubicin in the therapy of acute myeloid leukemia: final analysis in 57 previously untreated patients. Semin Oncol 1993; 20: 27-33.
30. Vogler WR, Velez Garcia E, Weiner RS et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol 1992; 10: 1103-1111.
31. Wiernik PH, Banks PL, Case DC Jr et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79: 313-319.
32. Avvisati G, Mandelli F, Petti MC et al. Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA. Eur J Haematol 1990; 44: 257-260.
33. Heyll A, Aul C, Gogolin F et al. Results of conventional-dose cytosine arabinoside and idarubicin in elderly patients with acute myeloid leukemia. Ann Hematol 1994; 68: 279-283.
34. Anderson JE, Appelbaum R, Schoch G et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors (see comments). J Clin Oncol 1996; 14: 220-226.
35. Carpenter PA, Marshall GM, Giri N et al. Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan. Bone Marrow Transplant 1996; 18: 489-494.
36. Lynch MH, Petersen FB, Appelbaum FR et al. Phase II study of busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for allogeneic bone marrow transplantation in patients with advanced myeloid malignancies. Bone Marrow Transplant 1995; 15: 59-64.
37. Uderzo C, Rondelli R, Dini G et al. High-dose vincristine, fractionated total-body irradiation and cyclophosphamide as conditioning regimen in allogeneic and autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission: a 7-year Italian multicentre study. Br J Haematol 1995; 89: 790-797.
38. Colleselli P, Dini G, Andolina M et al. Autologous bone marrow transplantation for acute lymphoblastic leukemia: the high dose vincristine study of AIEOP BMT group. Bone Marrow Transplant 1991; 3: 28-30.
39. Przepiorka D, Ippoliti C, Giralt S et al. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation. Bone Marrow Transplant 1994; 14: 449-453.
40. Przepiorka D, Nath R, Ippoliti C et al. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. Leuk Lymphoma 1995; 17: 427-433.
41. Cole CH, Pritchard S, Rogers PC et al. Intensive conditioning regimen for bone marrow transplantation in children with high-risk haematological malignancies. Med Pediatr Oncol 1994; 23: 464-469.
42. Cirait SA, LeMaistre CF, Vriesendorp HM et al. Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies. J Clin Oncol 1994; 12: 1923-1930.
43. Spitzer TR, Peters C, Ortlieb M et al, Etoposide in combination with cyclophosphamide and total body irradiation or busulfan as conditioning for marrow transplantation in adults and children. Int J Radiat Oncol Biol Phys 1994; 29: 39-44.
44. Wu DP, Milpied N, Moreau P et al. Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies. Bone Marrow Transplant 1994; 14: 751-757.
45. Crilley P, Topolsky D, Styler MJ et al. Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 361-365.
46. Van der Lely N, De Witte T, Raemaekers J et al. Anthracyclines added to the conditioning regimen for allogeneic bone marrow transplantation are associated with a slower haematopoietic recovery. Bone Marrow Transplant 1989; 4: 163-166.
47. Duncan N, Hewetson M, Powles R et al. An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma. Bone Marrow Transplant 1996; 18: 1175-1178.
48. Hartmann O, Le Corroller AG, Blaise D et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomised, controlled trial. Ann Intern Med 1997; 126: 600-607.
49. Smith TJ, Hillner BE, Schmitz N et al. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 5-10.
50. Henon P, Donatini B, Eisenmann JC et al. Comparative survival, quality of life and cost-effectiveness of intensive therapy with autologous blood cell transplantation or conventional chemotherapy in multiple myeloma. Bone Marrow Transplant 1995; 16: 19-25.
51. Lawless GD. Cost-effectiveness of autologous bone marrow transplantation. Am J Health Syst Pharm 1995; 52: S11-S14.
52. Faucher C, le Corroller AG, Biaise D et al. Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness. Bone Marrow Transplant 1994; 14: 895-901.